NCT03475459View on ClinicalTrials.gov

Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

April 29, 2018

Study Completion Date

April 29, 2018

Conditions
Qt Interval, Variation in
Interventions
DRUG

NPC-15 and/or Placebo

The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)

Trial Locations (1)

8120025

SOUSEIKAI Hakata Clinic, Fukuoka

Sponsors

Lead Sponsor

Nobelpharma
All Listed Sponsors
lead

Nobelpharma

INDUSTRY

NCT03475459 - Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7) | Biotech Hunter | Biotech Hunter